Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST.

Biochemistry. 2013 Dec 23;52(51):9155-66. doi: 10.1021/bi400945y. Epub 2013 Dec 13.

2.

Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.

Stec J, Fomovska A, Afanador GA, Muench SP, Zhou Y, Lai BS, El Bissati K, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Sommervile C, Woods S, Roberts CW, Rice D, Prigge ST, McLeod R, Kozikowski AP.

ChemMedChem. 2013 Jul;8(7):1138-60. doi: 10.1002/cmdc.201300050. Epub 2013 Jun 14.

3.

Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents.

Muench SP, Prigge ST, McLeod R, Rafferty JB, Kirisits MJ, Roberts CW, Mui EJ, Rice DW.

Acta Crystallogr D Biol Crystallogr. 2007 Mar;63(Pt 3):328-38. Epub 2007 Feb 21.

4.

Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Cheng G, Muench SP, Zhou Y, Afanador GA, Mui EJ, Fomovska A, Lai BS, Prigge ST, Woods S, Roberts CW, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Rice DW, McLeod R.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2035-43. doi: 10.1016/j.bmcl.2013.02.019. Epub 2013 Feb 13.

5.

Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase.

Muench SP, Prigge ST, Zhu L, Kirisits MJ, Roberts CW, Wernimont S, McLeod R, Rice DW.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jun 1;62(Pt 6):604-6. Epub 2006 May 31.

6.

High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan.

Otero JM, Noël AJ, Guardado-Calvo P, Llamas-Saiz AL, Wende W, Schierling B, Pingoud A, van Raaij MJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Oct 1;68(Pt 10):1139-48. doi: 10.1107/S1744309112033982. Epub 2012 Sep 22.

7.

The benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme target.

Wilkinson C, McPhillie MJ, Zhou Y, Woods S, Afanador GA, Rawson S, Khaliq F, Prigge ST, Roberts CW, Rice DW, McLeod R, Fishwick CW, Muench SP.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):911-6. doi: 10.1016/j.bmcl.2013.12.066. Epub 2013 Dec 22.

8.

Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.

Mehboob S, Truong K, Santarsiero BD, Johnson ME.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Nov 1;66(Pt 11):1436-40. doi: 10.1107/S1744309110039862. Epub 2010 Oct 27.

9.

Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.

Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL.

J Med Chem. 2010 Sep 9;53(17):6287-300. doi: 10.1021/jm9017724.

10.

Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.

Muench SP, Stec J, Zhou Y, Afanador GA, McPhillie MJ, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Prigge ST, Rice DW, McLeod R.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3551-5. doi: 10.1016/j.bmcl.2013.04.035. Epub 2013 Apr 24.

11.

An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.

Demissie RD, Kabre P, Tuntland ML, Fung LW.

J Biomol Screen. 2016 Apr;21(4):391-8. doi: 10.1177/1087057115615085. Epub 2015 Nov 4.

PMID:
26538431
12.

Structural basis and mechanism of enoyl reductase inhibition by triclosan.

Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C.

J Mol Biol. 1999 Jul 23;290(4):859-65.

PMID:
10398587
13.

Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.

Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ, Taylor IW.

Biochemistry. 1999 Sep 21;38(38):12514-25.

PMID:
10493822
15.

Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).

Zitko J, Doležal M.

Expert Opin Ther Pat. 2016 Sep;26(9):1079-94. doi: 10.1080/13543776.2016.1211112. Epub 2016 Jul 25. Review.

PMID:
27399249
16.

Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I.

McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE, Dorris M, Milhous WK, Rice DW.

Int J Parasitol. 2001 Feb;31(2):109-13.

PMID:
11239932
17.

Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase.

Kapoor N, Banerjee T, Babu P, Maity K, Surolia N, Surolia A.

IUBMB Life. 2009 Nov;61(11):1083-91. doi: 10.1002/iub.258.

18.

Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.

Lu H, Tonge PJ.

Biochemistry. 2010 Feb 16;49(6):1281-9. doi: 10.1021/bi902001a.

19.

Delivery of antimicrobials into parasites.

Samuel BU, Hearn B, Mack D, Wender P, Rothbard J, Kirisits MJ, Mui E, Wernimont S, Roberts CW, Muench SP, Rice DW, Prigge ST, Law AB, McLeod R.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14281-6. Epub 2003 Nov 17.

20.

Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.

Sivaraman S, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ.

J Med Chem. 2004 Jan 29;47(3):509-18.

PMID:
14736233

Supplemental Content

Support Center